These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18057521)

  • 21. Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases.
    Garg K; Park KJ; Soslow RA
    Int J Gynecol Pathol; 2012 Sep; 31(5):423-8. PubMed ID: 22833081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.
    Shih IeM; Chen L; Wang CC; Gu J; Davidson B; Cope L; Kurman RJ; Xuan J; Wang TL
    Am J Obstet Gynecol; 2010 Dec; 203(6):584.e1-22. PubMed ID: 20965493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
    Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
    Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
    Canet B; Pons C; Espinosa I; Prat J
    Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessing the landscape of ovarian serous borderline tumors.
    Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
    Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
    May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
    Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.
    Ayhan A; Kurman RJ; Yemelyanova A; Vang R; Logani S; Seidman JD; Shih IeM
    Am J Surg Pathol; 2009 Aug; 33(8):1220-4. PubMed ID: 19461510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
    Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
    Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-grade serous tumors of ovary.
    Bell DA
    Int J Gynecol Pathol; 2014 Jul; 33(4):348-56. PubMed ID: 24901394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors.
    Cîrstea AE; Stepan AE; Mărgăritescu C; Zăvoi RE; Olimid DA; Simionescu CE
    Rom J Morphol Embryol; 2017; 58(4):1269-1273. PubMed ID: 29556616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serous tumors of low malignant potential of the ovary-molecular pathology: part 2.
    Hauptmann S; Dietel M
    Virchows Arch; 2001 Jun; 438(6):539-51. PubMed ID: 11469685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
    Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.